TRON researchers contribute to newest BioNTech/Pfizer publication in Nature

Congratulations! TRON researcher Fulvia Vascotto was part of the team around Annette B. Vogel and Ugur Sahin, publishing pre-clinical results in Nature. The study supported the rapid development of BioNTech/Pfizer´s vaccine COMIRNATY (BNT162b2), the now globally deployed mRNA based vaccine against Covid-19. The recently published paper displays immune response data of two vaccine candidates (BNT162b1 and BNT162b2) in animal models. In mice, a single intramuscular dose of either candidate elicits a dose-dependent antibody response with high virus-entry inhibition titers and strong TH1 type CD4+ and IFNg+ CD8+ T-cell responses. Prime/boost vaccination of rhesus macaques with BNT162b candidates elicits SARS-CoV-2 neutralizing geometric mean titers 8.2 to 18.2 times that of a SARS-CoV-2 convalescent human serum panel.

To learn more, you can read the original publication here.